SACI-IO HR+: Ana Garrido-Castro, MD | Dana-Farber Cancer Institute [Video]

Antibody-drug conjugate plus a checkpoint inhibitor shows a trend toward improved survival in PD-L1-positive hormone receptor-positive, HER2-negative breast cancer. Dana-Farber’s Ana Garrido-Castro, MD, presented findings at #ASCO24. Video published 6/7/2024